IR
IRWD.US Ironwood Pharmaceuticals Inc
- Market cap
- USD 800M
- P/E
- 5.4x
- P/B
- 2.59x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is IRWD.US undervalued?
Graham numberIRWD.US trades 21.4% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ironwood Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Ironwood Pharmaceuticals Inc yet.
Ironwood Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZE…
Full company profileIronwood Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ironwood Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 274M | 298M | 347M | 428M | 390M | 414M | 411M | 443M | 351M | 296M | 470M |
| Gross Profit | 272M | 279M | 314M | 293M | 386M | 343M | 409M | 437M | 344M | 296M | 470M |
| Operating Income | -51.9M | -77.4M | -239M | 120M | 143M | 232M | 250M | -945M | 93.1M | 119M | 327M |
| EBITDA | -31.3M | -33.1M | -144M | 129M | 142M | 234M | 261M | 197M | 97.7M | 105M | 333M |
| Net Income | -81.7M | -117M | -282M | 21.5M | 106M | 528M | 175M | -1.00B | 880K | 24.0M | 203M |
| EPS | -0.56 | -0.78 | -1.85 | 0.14 | 0.66 | 3.21 | 0.94 | -6.45 | 0.01 | 0.14 | 1.22 |
| Balance Sheet | |||||||||||
| Total Assets | 710M | 606M | 332M | 403M | 559M | 1.13B | 1.10B | 471M | 351M | 397M | 291M |
| Total Liabilities | 643M | 596M | 528M | 496M | 497M | 521M | 448M | 817M | 652M | 659M | 388M |
| Shareholders' Equity | 66.7M | 9.85M | -196M | -93.3M | 62.6M | 606M | 652M | -346M | -301M | -262M | -97.2M |
| Cash & Short-term Investments | 305M | 221M | 173M | 177M | 364M | 620M | 656M | 92.2M | 88.6M | 215M | 86.4M |
| Total Debt | 373M | 400M | 414M | 431M | 454M | 476M | 416M | 716M | 599M | 598M | 11.2M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -25.4M | -99.6M | -70.9M | 10.7M | 169M | 262M | 274M | 183M | 104M | 127M | 174M |
| Capital Expenditure | 104M | 4.21M | 8.62M | 7.19M | 1.84M | 265K | 136K | 273K | 142K | 34.0K | 0.00 |
| Free Cash Flow | -130M | -104M | -79.5M | 3.54M | 167M | 262M | 274M | 183M | 103M | 127M | 174M |
| Ratios | |||||||||||
| ROE | -122.5% | -1,187.4% | - | - | 169.5% | 87.2% | 26.8% | - | - | - | - |
| ROA | -11.5% | -19.3% | -85.0% | 5.3% | 19.0% | 46.9% | 15.9% | -212.8% | 0.3% | 6.1% | 69.7% |
| Net Profit Margin | -29.8% | -39.2% | -81.5% | 5.0% | 27.3% | 127.7% | 42.6% | -226.4% | 0.3% | 8.1% | 43.1% |
| Debt to Equity | 5.59x | 40.63x | - | - | 7.24x | 0.79x | 0.64x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Ironwood Pharmaceuticals Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 111M | 0.60 | 63.5% |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1194:1000 on Apr 2, 2019.
Who owns Ironwood Pharmaceuticals Inc
- Insiders 3.51%
- Institutions 96.49%
- Public & others 0.00%
- Shares outstanding 166M
- Free float 137M
Top funds holding IRWD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 4.78M | 2.89% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 4.14M | 2.50% | 0.00% | Oct 2026 |
| State Street® SPDR® S&P® Biotech ETF | 3.56M | 2.15% | +2.69% | Oct 2026 |
| Fidelity Small Cap Index | 1.79M | 1.08% | 0.00% | Aug 2026 |
| Vanguard Strategic Equity Inv | 1.60M | 0.97% | -8.62% | Sep 2026 |
| Bridge Builder Small Cap Fund | 1.57M | 0.95% | +77.64% | Oct 2026 |
| iShares Russell 2000 Growth ETF | 1.46M | 0.88% | -0.38% | Oct 2026 |
| Pacer US Small Cap Cash Cows 100 ETF | 1.32M | 0.80% | +0.23% | Oct 2026 |
| Federated Hermes MDT Small Cap Core IS | 1.29M | 0.78% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 1.26M | 0.76% | -0.19% | Oct 2026 |
| Fidelity Enhanced Small Cap Core ETF | 1.12M | 0.68% | +0.27% | Oct 2026 |
| BlackRock Advantage Small Cap Core Instl | 1.08M | 0.65% | +0.46% | Sep 2026 |
| Vanguard Explorer Inv | 1.04M | 0.63% | -25.88% | Sep 2026 |
| Canada Life US Small-Mid Cap Growth F | 978K | 0.59% | 0.00% | Aug 2026 |
| Vanguard Russell 2000 ETF | 951K | 0.57% | +1.11% | Sep 2026 |
| Schwab Fundamental U.S. Small CompanyETF | 898K | 0.54% | 0.00% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 814K | 0.49% | +0.24% | Oct 2026 |
| Federated Hermes MDT Small Cap Growth IS | 732K | 0.44% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 691K | 0.42% | -1.02% | Sep 2026 |
| First Trust Dow Jones Sel MicroCap ETF | 663K | 0.40% | 0.00% | Oct 2026 |
Top institutions holding IRWD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 17.8M | 10.75% | +33.12% | Jun 2026 |
| Armistice Capital, LLC | 13.9M | 8.42% | -7.29% | Jun 2026 |
| Sarissa Capital Management LP | 9.19M | 5.55% | 0.00% | Jun 2026 |
| State Street Corp | 8.81M | 5.32% | +18.14% | Jun 2026 |
| Bank of America Corp | 8.68M | 5.25% | +0.01% | Jun 2026 |
| Renaissance Technologies Corp | 8.04M | 4.86% | +0.61% | Sep 2026 |
| Vanguard Capital Management, LLC | 6.61M | 3.99% | +8.38% | Jun 2026 |
| AQR Capital Management LLC | 6.47M | 3.91% | -14.19% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 5.51M | 3.33% | -17.49% | Jun 2026 |
| Acadian Asset Management LLC | 5.05M | 3.05% | -13.69% | Sep 2026 |
| Geode Capital Management, LLC | 4.83M | 2.92% | +6.34% | Jun 2026 |
| Two Sigma Investments LLC | 4.56M | 2.75% | -22.10% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 4.29M | 2.59% | -5.19% | Jun 2026 |
| Jacobs Levy Equity Management, Inc. | 4.07M | 2.46% | +11.93% | Jun 2026 |
| The Goldman Sachs Group Inc | 3.31M | 2.00% | +23.16% | Jun 2026 |
| Charles Schwab Investment Management Inc | 3.30M | 1.99% | -30.30% | Jun 2026 |
| Federated Hermes Inc | 3.23M | 1.95% | -3.51% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 3.02M | 1.82% | -11.19% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 2.65M | 1.60% | +5.22% | Sep 2026 |
| Mackenzie Investments | 2.37M | 1.43% | +322.74% | Jun 2026 |
Ironwood Pharmaceuticals Inc company profile
- Company name
- Ironwood Pharmaceuticals Inc
- Ticker
- IRWD.US
- Exchange
- USA Stocks
- Listed since
- Feb 3, 2010
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 100
- Fiscal year end
- December
- Address
- 100 Summer Street, Boston, MA, United States, 02110
- Phone
- 617 621 7722
- Website
- ironwoodpharma.com
About Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Ironwood Pharmaceuticals Inc management
8- Mr. Thomas A. McCourtCEO & Director · born 1957
- Ms. Tammi GaskinsSenior Vice President & Chief Commercial Officer · born 1973
- Mr. Ronald SilverSenior VP, Interim CFO, Corporate Controller & Chief Accounting Officer · born 1982
- Dr. Rosario Lobrutto M.B.A., M.S., Ph.D.VP & Global Head of Technical Operations
- Mr. Chris StammVice President of Investor Relations & Communications
- Mr. John MinardoSenior VP, Chief Legal Officer & Secretary · born 1976
- Mr. Jeff RubertiChief Strategy Officer
- Dr. Jeffrey Silber M.D.Chief Medical Officer, Head of Research & Drug Development